Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling
Today's drug candidates are more complex than ever. But with development decisions on the line,…
Certara2025 年 2 月 12 日
Machine Learning for Population PK Model Selection: Theory and Practice
Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…
Danielle Pillsbury2025 年 2 月 7 日
Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling
With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…
Danielle Pillsbury2025 年 2 月 7 日
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies
This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…
Danielle Pillsbury2025 年 2 月 6 日
Understanding Variability in CAR-T Cell Therapy Kinetics
Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…
Danielle Pillsbury2025 年 1 月 23 日
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)
In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…
Danielle Pillsbury2025 年 1 月 9 日
Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development
At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…
Certara2024 年 12 月 10 日
